TISSUE FACTOR PRODUCTION INHIBITOR

Title:

TISSUE FACTOR PRODUCTION INHIBITOR

Document Type and Number:

WIPO Patent Application WO/2006/004030

Kind Code:

A1

Abstract:

A pharmaceutical having the potency of inhibiting the production of tissue factors, which pharmaceutical comprises an LXR ligand as an active ingredient. There is provided a pharmaceutical for the treatment and/or prevention of vascular re-stenosis encountered after angioplasty, endarterectomy, percutaneous coronary angioplasty (PTCA) or stent placement, or for the treatment and/or prevention of blood coagulation disorder, diseases induced by platelet aggregation including stable or unstable angina, disorders of cardiovascular and cerebrovascular systems including thromboembolism induced by diabetes, re-thrombosis encountered after thrombolysis, brain ischaemia seizure, infarction, apoplexy, dementia resulting from ischemia, peripheral arterial disease, thromboembolism encountered during the use of aortocoronary bypass, glomerulosclerosis, kidney embolism, tumor or cancer metastasis, which pharmaceutical comprises an LXR ligand as an active ingredient.

More Like This:

WO/1991/005761	TREATMENT OF HIV INFECTIONS AND COMPOUNDS USEFUL THEREIN
WO/2004/014367	USE OF AN AMYLOID BETA VACCINATION IN COMBINATION WITH A SELECTIVE COX-2 INHIBITOR FOR THE TREATMENT OF ALZHEIMER'S DISEASE
WO/2015/110262	NOVEL CYP-EICOSANOID DERIVATIVES

Inventors:

TERASAKA NAOKI (JP)
HIROSHIMA AYANO (JP)

Application Number:

PCT/JP2005/012185

Publication Date:

January 12, 2006

Filing Date:

July 01, 2005

Export Citation:

Click for automatic bibliography generation Help

Assignee:

SANKYO CO (JP)
TERASAKA NAOKI (JP)
HIROSHIMA AYANO (JP)

International Classes:

A61K31/18; A61K31/404; A61K31/423; A61K31/517; A61K31/5377; A61K45/00; A61K9/10; A61P13/12; A61P35/00; A61P35/04; A61P43/00; A61P7/02; A61P9/00; C07D239/70; C07D239/90; C07D239/91; C07D261/20; C07D401/04; C07D401/06; C07D401/12; C07D403/04; C07D403/06; C07D403/12; C07D409/04; C07D417/04; C07J9/00; (IPC1-7): A61K45/00; A61K9/10; A61K31/18; A61K31/404; A61K31/423; A61K31/517; A61K31/5377; A61P7/02; A61P9/00; A61P13/12; A61P35/00; A61P35/04; A61P43/00; C07D239/70; C07D239/90; C07D239/91; C07D261/20; C07D401/04; C07D401/06; C07D401/12; C07D403/04; C07D403/06; C07D403/12; C07D409/04; C07D417/04; C07J9/00

Domestic Patent References:

WO2003106435A1

2003-12-24

Other References:

ELISAF M. ET AL: "Effects of fibrates on serum metabolic parameters.", CURR MED RES OPIN., vol. 18, no. 5, 2002, pages 269 - 276, XP002991327
TERASAKAN N. ET AL: "Liver X receptor agonist inhibit tissue factor expression in macrophages.", FEBS J., vol. 272, no. 6, 2005, pages 1546 - 1556, XP002991328
See also references of EP 1764075A4

Attorney, Agent or Firm:

SIKs & Co. (Kyobashi-Nisshoku Bldg. 8-7, Kyobashi 1-chom, Chuo-ku Tokyo 31, JP)

Download PDF:

View/Download PDF PDF Help

Previous Patent: FUEL SUPPLY SYSTEM FOR INTERNAL COMBUSTION ENGINE

Next Patent: ALKALINE DRY CELL